ETTX - Zai Lab and Entasis complete enrollment in late-stage sulbactam-durlobactam study

Zai Lab (ZLAB) and Entasis Therapeutics (ETTX) announce the completion of enrollment in the late-stage trial of sulbactam-durlobactam (SUL-DUR) in patients with confirmed carbapenem-resistant Acinetobacter infections.The company said that it expects to post top-line data readout from the study early in the fourth quarter of 2021.The trial, which has already enrolled over 120 patients, will study the primary endpoint of 28-day all-cause mortality.Acinetobacter is a gram-negative human pathogen that predominantly infects critically ill patients often resulting in severe pneumonia and bloodstream infections.MacroGenics and Zai Lab entered into an exclusive collaboration and license agreement involving up to four immuno-oncology molecules, last month.

For further details see:

Zai Lab and Entasis complete enrollment in late-stage sulbactam-durlobactam study